Spyre Therapeutics Inc (SYRE) акции достигли 52-ти недельного максимума в 108,16 долара во вторник, продолжая сильную ралли, которое принесло 517% годовых доходов за последнее время и 219% рост за последний год.
Biotech firm, which boasts a market capitalization of $9.5 billion, has attracted significant analyst attention following positive phase 2 trial results for its ulcerative colitis treatment SPY002. The trial, which enrolled 48 patients, demonstrated a statistically significant improvement in Robart's Histopathology Index score at week 12, according to company data.
Analysts have offered mixed but generally bullish outlooks. Mizuho raised its price target to $120, citing promising clinical remission rates from the SKYLINE Part A data. Deutsche Bank also raised its target to $115, citing partly the setback of a rival in a related trial. Wolfe Research, however, downgraded Spyre to Peerperform, citing valuation concerns and potential third-quarter catalysts.
Akciová cesta se rovněž shodovala s významnou aktivitou insiderů. Fairmount Healthcare Fund II L.P. prodala více než 4,6 milionu akcií za přibližně 399,7 milionu dolarů a úplně opustila pozici. Analýza InvestingPro naznačuje, že akcie mohou být nadhodnoceny ve srovnání se svou hodnotou podle modelu a zůstává silným názorem pro nákup od analytiků.
